ImmuneSensor Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- ImmuneSensor Therapeutics's estimated annual revenue is currently $930k per year.
- ImmuneSensor Therapeutics's estimated revenue per employee is $77,500
Employee Data
- ImmuneSensor Therapeutics has 12 Employees.
- ImmuneSensor Therapeutics grew their employee count by -20% last year.
ImmuneSensor Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Co-Founder and Chairman | Reveal Email/Phone |
3 | Acting Chief Medical Officer | Reveal Email/Phone |
4 | VP, Clinical Operations and Project Management | Reveal Email/Phone |
5 | VP Finance | Reveal Email/Phone |
6 | VP, Regulatory | Reveal Email/Phone |
7 | Senior Director, Clinical Operations and Project Management | Reveal Email/Phone |
8 | Associate Director Biology Department | Reveal Email/Phone |
9 | Principal Investigator | Reveal Email/Phone |
10 | Senior Scientist | Reveal Email/Phone |
ImmuneSensor Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.5M | 16 | 45% | N/A | N/A |
#2 | $13.8M | 89 | -7% | N/A | N/A |
#3 | $18.6M | 120 | 3% | $1.8M | N/A |
#4 | $0.9M | 6 | -40% | N/A | N/A |
#5 | $4.2M | 27 | 0% | N/A | N/A |
#6 | $3.4M | 22 | 47% | N/A | N/A |
#7 | $9.6M | 62 | 29% | N/A | N/A |
#8 | $0.9M | 6 | 20% | N/A | N/A |
#9 | $1.7M | 11 | 10% | N/A | N/A |
#10 | $15.2M | 98 | -8% | N/A | N/A |
What Is ImmuneSensor Therapeutics?
ImmuneSensor is developing novel medicines that target the cGAS (cyclic GMP-AMP synthase) - STING (stimulator of interferon genes) pathway of the innate immune system to treat cancer and autoimmune diseases. The Company has licensed technologies from the laboratory of Dr. Zhijian \James\ Chen, Professor of Molecular Biology at the University of Texas Southwestern Medical Center and Investigator of Howard Hughes Medical Institute. Dr. Chen discovered cGAS and its product cGAMP, which activates STING to stimulate immune responses. These discoveries form the technological foundation of ImmuneSensor. The company's pipeline consists of both STING activators to boost anticancer immunity and also cGAS inhibitors to suppress overactivated autoimmunity. ImmuneSensor's lead program, IMSA101 is a STING activator currently in clinical development for cancer therapy.
keywords:N/A
N/A
Total Funding
12
Number of Employees
$930k
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Dallas
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1M | 12 | -33% | N/A |
#2 | $0.4M | 12 | -29% | $11.4M |
#3 | $1M | 12 | N/A | N/A |
#4 | $2.2M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |